Aliases & Classifications for Cocaine Abuse

MalaCards integrated aliases for Cocaine Abuse:

Name: Cocaine Abuse 12 52 14 69
Cocaine-Related Disorders 42 69

Classifications:



External Ids:

Disease Ontology 12 DOID:809
ICD10 33 F14.1
ICD9CM 35 305.6 305.60
MeSH 42 D019970
SNOMED-CT 64 78267003
UMLS 69 C0009171

Summaries for Cocaine Abuse

Disease Ontology : 12 A substance abuse that involves the recurring use of cocaine despite negative consequences.

MalaCards based summary : Cocaine Abuse, also known as cocaine-related disorders, is related to alcoholic liver cirrhosis and personality disorder. An important gene associated with Cocaine Abuse is SLC6A3 (Solute Carrier Family 6 Member 3), and among its related pathways/superpathways are Circadian entrainment and NRF2 pathway. The drugs Amphetamine and Cocaine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and uterus, and related phenotypes are Decreased viability and behavior/neurological

Related Diseases for Cocaine Abuse

Diseases related to Cocaine Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 152)
id Related Disease Score Top Affiliating Genes
1 alcoholic liver cirrhosis 29.9 DRD2 PRL SLC6A4
2 personality disorder 29.2 DRD2 SLC6A2 SLC6A3 SLC6A4 SNCA
3 schizophrenia 27.4 DBH DRD2 HTR3A PRL SLC18A2 SLC6A2
4 rhinoscleroma 10.6 DRD2 PRL
5 water-clear cell adenoma 10.6 DRD2 PRL
6 hyperthyroxinemia 10.6 DRD2 SLC6A4
7 peroxisomal biogenesis disorders 10.6 DRD2 PRL
8 vasculogenic impotence 10.5 DRD2 SNCA
9 sebaceous gland disease 10.5 SLC6A3 SNCA
10 pompholyx 10.5 DRD2 SLC6A4
11 strabismus 10.5 DRD2 PRL
12 anosognosia 10.5 DRD2 SLC6A4
13 tinea pedis 10.5 SLC6A3 SLC6A4
14 eosinophilia-myalgia syndrome 10.5 DRD2 SLC6A3
15 tubular variant testicular seminoma 10.5 SLC6A2 SLC6A3
16 intracranial cavernous angioma 10.4 DRD2 SLC6A3 SLC6A4
17 splenic abscess 10.4 DRD2 SLC6A3 SLC6A4
18 pyromania 10.4 DRD2 SLC6A3 SLC6A4
19 tongue disease 10.4 DRD2 SLC6A3 SLC6A4
20 central cervical cord syndrome 10.4 DBH SNCA
21 cecal benign neoplasm 10.4 DRD2 SLC6A3 SLC6A4
22 luxation of globe 10.4 PRL SLC6A4
23 perinatal necrotizing enterocolitis 10.4 DRD2 SLC6A3 SLC6A4
24 heroin dependence 10.4 DRD2 SLC6A3 SLC6A4
25 hypertrophy of breast 10.4 PRL SLC6A3
26 bladder flat intraepithelial lesion 10.3 DRD2 PRL SLC6A4
27 simpson-golabi-behmel syndrome 10.3 DBH DRD2 SLC6A3
28 angiokeratoma of mibelli 10.3 SLC6A2 SLC6A4
29 pervasive developmental disorder 10.3 SLC6A2 SLC6A3 SLC6A4
30 pelvic inflammatory disease 10.3 DBH DRD2 SLC6A4
31 anodontia 10.2 HTR3A SLC6A3 SLC6A4
32 bone fracture 10.2 DRD2 SLC6A3 SLC6A4
33 contact dermatitis 10.2 DRD2 SLC18A2 SLC6A3
34 cold-induced sweating syndrome 2 10.2 DRD2 PRL
35 long qt syndrome-11 10.2 DBH DRD2
36 microcephaly 18, primary, autosomal dominant 10.1 SLC18A2 SLC6A3 SNCA
37 albinism, oculocutaneous, type v 10.1 DRD2 HTR3A SLC6A4
38 perry syndrome 10.1 SLC18A2 SLC6A3 SNCA
39 ovarian cystadenocarcinoma 10.1 SLC18A2 SLC6A3 SNCA
40 renpenning syndrome 10.1 DBH HTR3A SLC6A4
41 may-hegglin anomaly 10.1 HTR3A SLC6A2 SLC6A4
42 autoimmune-related retinopathy and optic neuropathy 10.1 HTR3A PRL SLC6A4
43 adrenal gland pheochromocytoma 10.1 SLC18A2 SLC6A3 SNCA
44 pyogenic arthritis, pyoderma gangrenosum and acne 10.1 DBH SNCA
45 cerebritis 10.1
46 parkinson disease 1 10.1 SLC18A2 SLC6A3 SNCA
47 carotid stenosis 10.0 DBH DRD2 SLC6A3 SLC6A4
48 ornithosis 10.0 DRD2 HTR3A PRL SLC6A4
49 parietal foramina 3 10.0 DBH DRD2 SLC6A3 SNCA
50 myocardial infarction 10.0

Comorbidity relations with Cocaine Abuse via Phenotypic Disease Network (PDN):


Alcohol Abuse

Graphical network of the top 20 diseases related to Cocaine Abuse:



Diseases related to Cocaine Abuse

Symptoms & Phenotypes for Cocaine Abuse

GenomeRNAi Phenotypes related to Cocaine Abuse according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.1 HTR3A SIGMAR1 SLC6A4
2 Decreased viability GR00381-A-3 9.1 HTR3A SIGMAR1 SLC6A4

MGI Mouse Phenotypes related to Cocaine Abuse:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.14 DBH DRD2 HTR3A PRL SIGMAR1 SLC17A8
2 growth/size/body region MP:0005378 9.92 DBH DRD2 HTR3A SLC18A2 SLC6A2 SLC6A3
3 endocrine/exocrine gland MP:0005379 9.91 DBH DRD2 HTR3A PRL SLC6A3 SLC6A4
4 homeostasis/metabolism MP:0005376 9.91 DBH DRD2 HTR3A PRL SLC18A2 SLC6A2
5 integument MP:0010771 9.81 DBH DRD2 HTR3A PRL SLC17A8 SLC6A2
6 nervous system MP:0003631 9.65 DBH DRD2 HTR3A PRL SLC17A8 SLC18A2
7 taste/olfaction MP:0005394 9.02 SLC18A2 SLC6A3 SNCA DRD2 GRK3

Drugs & Therapeutics for Cocaine Abuse

Drugs for Cocaine Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 292)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amphetamine Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 300-62-9 5826 3007
2
Cocaine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-36-2 5760 446220
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
4
Risperidone Approved, Investigational Phase 4,Phase 2,Phase 1 106266-06-2 5073
5
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1 76-99-3 4095
6
Amantadine Approved Phase 4,Phase 2,Phase 1 768-94-5 2130
7
Carbamazepine Approved, Investigational Phase 4,Phase 2 298-46-4 2554
8
Heroin Approved, Illicit Phase 4,Phase 3,Phase 1 561-27-3 5462328
9
Oxytocin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-56-6 439302 53477758
10
Choline Approved, Nutraceutical Phase 4,Phase 3 62-49-7 305
11 Adrenergic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
12 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
13 Anesthetics, Local Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
14 Antipsychotic Agents Phase 4,Phase 2,Phase 1,Early Phase 1
15 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
16 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Central Nervous System Stimulants Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
18 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Dopamine Antagonists Phase 4,Phase 2,Phase 1,Early Phase 1
20 Dopamine Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
21 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 Quetiapine Fumarate Phase 4,Phase 1 111974-72-2
26
Serotonin Phase 4,Phase 2,Phase 3,Phase 1 50-67-9 5202
27 Serotonin Agents Phase 4,Phase 2,Phase 3,Phase 1
28 Serotonin Antagonists Phase 4,Phase 2,Phase 1
29 Tranquilizing Agents Phase 4,Phase 2,Phase 1,Early Phase 1
30 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Opiate Alkaloids Phase 4,Phase 2,Phase 1
32 Antimetabolites Phase 4,Phase 2,Phase 1
33 Gastrointestinal Agents Phase 4,Phase 2
34 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
35 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 1
36 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Antiparkinson Agents Phase 4,Phase 2,Phase 3,Phase 1
38 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1
39 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 2,Phase 1
40 Cytidine Diphosphate Choline Phase 4,Phase 3
41 Hypolipidemic Agents Phase 4
42 Lipid Regulating Agents Phase 4
43 Nootropic Agents Phase 4,Phase 3,Phase 2
44 Antiviral Agents Phase 4,Phase 2,Phase 1,Early Phase 1
45 Antimanic Agents Phase 4,Phase 2,Phase 1
46 Oxytocics Phase 4,Phase 2,Phase 3,Phase 1
47 Lecithin Nutraceutical Phase 4
48
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 52485-79-7 40400 644073
49
Topiramate Approved Phase 3,Phase 2,Phase 1 97240-79-4 5284627
50
Citalopram Approved Phase 2, Phase 3,Phase 1 59729-33-8 2771

Interventional clinical trials:

(show top 50) (show all 334)

id Name Status NCT ID Phase Drugs
1 Cognitive Correlates of Substance Abuse - 11 Unknown status NCT00000346 Phase 4
2 Cognitive Correlates of Substance Abuse, Part 2 - 16 Unknown status NCT00000351 Phase 4
3 Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia Completed NCT00208143 Phase 4 Quetiapine;Risperidone
4 The Maternal Lifestyle Study (MLS) Completed NCT00059540 Phase 4
5 Citicoline for Bipolar 1 Disorder and Cocaine Dependence Completed NCT00619723 Phase 4 Citicoline;Placebo
6 Pathophysiological Subtyping of Abnormalities in Cocaine Dependence - 9 Completed NCT00015275 Phase 4
7 Relapse Patterns in Female Cocaine Users - 4 Completed NCT00000287 Phase 4
8 Modeling Impaired Judgement in Cocaine Abusers - 6 Completed NCT00015236 Phase 4
9 Pharmacotherapy and Intensive Treatment - 2 Completed NCT00000218 Phase 4 Carbamazepine
10 Oxytocin and Cognitive Behavioral Therapy in Drug Dependence Terminated NCT00975416 Phase 4 Intranasal Oxytocin;Placebo
11 Brain Imaging: Cocaine Effects & Medication Development - 5 Withdrawn NCT00000270 Phase 4 Cocaine
12 Combining Behavioral Treatment With Agonist Maintenance - 1 Unknown status NCT00000311 Phase 3 Buprenorphine
13 Effectiveness of Topiramate in Treating Cocaine Dependent Individuals - 1 Unknown status NCT00249691 Phase 3 Topiramate + Cognitive Behavioral Therapy;Placebo + Cognitive Behavioral Therapy
14 Trial of Citicoline Therapy in Patients With Mania or Hypomania and Cocaine Abuse/Dependence Completed NCT00223236 Phase 3 Citicoline;Placebo
15 Effect of Nefazodone on Relapse in Females With Cocaine Abuse - 10 Completed NCT00000293 Phase 3 Nefazodone
16 Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence Completed NCT00553319 Phase 2, Phase 3 Placebo;Adderall-XR;Adderall-XR
17 Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1 Completed NCT00032929 Phase 3 Selegiline
18 Cocaine Use Reduction With Buprenorphine Completed NCT01402492 Phase 2, Phase 3 Buprenorphine + Naltrexone;Placebo + Naltrexone
19 An Eval of Neurocognitive Function, Oxidative Damage, and Their Association With Outcomes in METH and Cocaine Abusers. Completed NCT00628927 Phase 3
20 Clinical Neurobiology of Serotonin and Addiction Completed NCT00732901 Phase 2, Phase 3 Escitalopram;Placebo
21 Smoking-Cessation and Stimulant Treatment (S-CAST) Completed NCT01077024 Phase 3
22 Buprenorphine Maintenance for Cocaine Abusing Opioid Addicts - 1 Completed NCT00000216 Phase 3 Buprenorphine
23 Stimulant Abuser Groups to Engage in 12-Step Completed NCT00573183 Phase 3
24 Reinforcement-Based Treatment for Pregnant Drug Abusers Completed NCT01177982 Phase 2, Phase 3
25 Motivational Incentives for Enhanced Drug Abuse Recovery: Drug Free Clinics - 1 Completed NCT00033007 Phase 3
26 Vigabatrin for the Treatment of Cocaine Dependency Completed NCT01281202 Phase 2, Phase 3 Vigabatrin;Matching Placebo
27 Motivational Incentives for Enhanced Drug Abuse Recovery: Methadone Clinics. - 1 Completed NCT00033020 Phase 3
28 "Effectiveness of a Brief Intervention for Substances Consumption Linked to the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): A Randomized Control Trial in Chilean Primary Care." Completed NCT01573416 Phase 3
29 Brief Intervention to Reduce STDs in ER Drug Users Completed NCT01379599 Phase 3
30 Progesterone Treatment for Cocaine-dependent Women: A Pilot Study Completed NCT00632099 Phase 2, Phase 3 Oral micronized progesterone;Placebo
31 Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence Completed NCT01811940 Phase 2, Phase 3 Adderall-ER;Topiramate
32 Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence - 1 Completed NCT00218660 Phase 3 Naltrexone;Placebo
33 Dose Response Trial of Pergolide for Cocaine Dependence - 1 Completed NCT00000248 Phase 3 Pergolide
34 Bupropion-Enhanced Contingency Management (CM) for Cocaine Dependence Recruiting NCT02111798 Phase 2, Phase 3 Bupropion XL;placebo
35 Investigation of Intranasal Oxytocin on Relapse Risk in Cocaine-dependent Patients. Active, not recruiting NCT02255357 Phase 2, Phase 3 Placebo;Intranasal Oxytocin
36 Treating Cocaine Abuse: A Behavioral Approach Unknown status NCT01822327 Phase 2
37 Pharmacotherapy Dosing Regimen in Cocaine and Opiate Dependent Individuals - 8 Unknown status NCT00218036 Phase 2 Modafinil 200mg;Modafinil 400mg;Citalopram 20mg;Citalopram 40mg;Placebo
38 Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD) Completed NCT00218543 Phase 2 Atomoxetine
39 Pemoline for Cocaine Abuse - 7 Completed NCT00000282 Phase 2 Pemoline
40 Mazindol for Cocaine Abuse - 2 Completed NCT00000277 Phase 2 Mazindol
41 Disulfiram for Cocaine Abuse in Buprenorphine Treatment Completed NCT00913484 Phase 2 Disulfiram;Placebo
42 Evaluation of a Desipramine Ceiling in Cocaine Abuse - 1 Completed NCT00000245 Phase 2 Desipramine
43 The Efficacy of Methadyl Acetate (LAAM) and Contingency Management Procedures for Treating Dual Opioid and Cocaine Abuse - 1 Completed NCT00158288 Phase 2
44 Cocaine Abuse and ADHD - 10 Completed NCT00000275 Phase 2 Flupenthixol
45 Disulfiram for Cocaine Abuse Completed NCT00395850 Phase 2 Disulfiram
46 IV Cocaine Abuse: A Laboratory Model - 3 Completed NCT00000214 Phase 2 Buprenorphine
47 IV Cocaine Abuse: A Laboratory Model - 2 Completed NCT00000213 Phase 2 Fluoxetine
48 IV Cocaine Abuse: A Laboratory Model - 4 Completed NCT00000215 Phase 2 Pergolide
49 IV Cocaine Abuse: A Laboratory Model - 1 Completed NCT00000212 Phase 2 Desipramine
50 New Approaches to Cocaine Abuse Medications (A) - 6 Completed NCT00000271 Phase 2 Desipramine;Placebo

Search NIH Clinical Center for Cocaine Abuse

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: cocaine-related disorders

Genetic Tests for Cocaine Abuse

Anatomical Context for Cocaine Abuse

MalaCards organs/tissues related to Cocaine Abuse:

39
Brain, Testes, Uterus, Placenta, Lung, Pituitary, Amygdala

Publications for Cocaine Abuse

Articles related to Cocaine Abuse:

(show top 50) (show all 585)
id Title Authors Year
1
Botryoid nuclei resulting from cocaine abuse. ( 28439943 )
2017
2
Resting state brain connectivity patterns before eventual relapse into cocaine abuse. ( 28057531 )
2017
3
Internuclear Ophthalmoplegia Secondary to Cocaine Abuse. ( 28265477 )
2017
4
Towards an automatic lab-on-valve-ion mobility spectrometric system for detection of cocaine abuse. ( 28712550 )
2017
5
Impact on Cortical Function of Cocaine Abuse Co-Occurring with HIV. ( 27909321 )
2017
6
The Novel Modafinil Analog, JJC8-016, as a Potential Cocaine Abuse Pharmacotherapeutic. ( 28266501 )
2017
7
Chronic orbital inflammatory disease and optic neuropathy associated with long-term intranasal cocaine abuse: 2 cases and literature review. ( 28812909 )
2017
8
A tip from the nose: rhinocerebral mucormycosis in a patient with alcoholic liver cirrhosis and cocaine abuse, an uncommon association. ( 28784893 )
2017
9
Multi-System Complications after Intravenous Cocaine Abuse. ( 28507634 )
2017
10
Cocaine Abuse, Traumatic Brain Injury, and Preexisting Brain Lesions as Risk Factors for Bupropion-Associated Psychosis. ( 28590371 )
2017
11
Cocaine abuse determination by ion mobility spectrometry using molecular imprinting. ( 28012589 )
2017
12
The Use of Intraoperative Transesophageal Echocardiography in Thoracic Aortic Dissection Due to Chronic Cocaine Abuse. ( 28920034 )
2017
13
Role of Sigma-1 Receptor in Cocaine Abuse and Neurodegenerative Disease. ( 28315271 )
2017
14
Cocaine and crack cocaine abuse by pregnant or lactating mothers and analysis of its biomarkers in meconium and breast milk by LC-MS-A review. ( 26827634 )
2016
15
Multiple Pyoderma Gangrenosum Ulcers Associated with Cocaine Abuse. ( 28003907 )
2016
16
Cocaine abuse and effects in the serum levels of cytokines IL-6 and IL-10. ( 26679059 )
2016
17
Increased MFG-E8 expression and its implications in the vascular pathophysiology of cocaine abuse. ( 27182119 )
2016
18
A case of iloperidone overdose in a 27-year-old man with cocaine abuse. ( 27570623 )
2016
19
Adolescent d-amphetamine treatment in a rodent model of attention deficit/hyperactivity disorder: impact on cocaine abuse vulnerability in adulthood. ( 27600990 )
2016
20
The Ventral Pallidum: Proposed Integrator of Positive and Negative Factors in Cocaine Abuse. ( 27710789 )
2016
21
Plasma Selenium Levels in Chronic Cocaine Abuse. ( 27349018 )
2016
22
Plant expression of cocaine hydrolase-Fc fusion protein for treatment of cocaine abuse. ( 27756365 )
2016
23
Cocaine abuse that presents with acute scrotal pain and mimics testicular torsion. ( 27583357 )
2016
24
Extensive Necrotic Purpura in Levamisole-Adulterated Cocaine Abuse - A Case Report. ( 27500987 )
2016
25
Cocaine Abuse: An Unusual Association. ( 27805341 )
2016
26
Multifocal and refractory pyoderma gangrenosum: Possible role of cocaine abuse. ( 27250583 )
2016
27
Relationship between coronary artery ectasia, cocaine abuse and acute coronary syndromes. ( 27231522 )
2016
28
Behaviour of hygrine and cuscohygrine in illicit cocaine production establishes their use as markers for chewing coca leaves in contrast with cocaine abuse. ( 27004438 )
2016
29
The absence of VGLUT3 predisposes to cocaine abuse by increasing dopamine and glutamate signaling in the nucleus accumbens. ( 26239290 )
2015
30
Atraumatic splenic rupture and ileal volvulus following cocaine abuse. ( 26324218 )
2015
31
Neuropsychological impairments associated with the relation between cocaine abuse and violence: neurological facilitation mechanisms. ( 25879478 )
2015
32
The most dangerous complication of intranasal cocaine abuse in a young man: cardiac arrest. ( 26778640 )
2015
33
Cocaine abuse, retiform purpura and antiphospholipid syndrome. ( 26070938 )
2015
34
Cocaine Abuse in Later Life: A Case Series and Review of the Literature. ( 26445694 )
2015
35
Investigating the potential influence of cause of death and cocaine levels on the differential expression of genes associated with cocaine abuse. ( 25658879 )
2015
36
Effectiveness of secondary prevention and treatment interventions for crack-cocaine abuse: A comprehensive narrative overview of English-language studies. ( 25662894 )
2015
37
Identification of long noncoding RNAs dysregulated in the midbrain of human cocaine abusers. ( 26222413 )
2015
38
Platelet Activation in Human Immunodeficiency Virus Type-1 Patients Is Not Altered with Cocaine Abuse. ( 26076359 )
2015
39
Prosthetic Management for a Palatal Perforation from Cocaine Abuse. ( 25557361 )
2015
40
Assessing cocaine abuse using LC-MS/MS measurements in biological specimens. ( 26168256 )
2015
41
Impact of cocaine abuse on HIV pathogenesis. ( 26539167 )
2015
42
Membranous glomerulonephritis and cellular crescents induced by levamisole-adulterated cocaine abuse: a case report. ( 26605317 )
2015
43
Pyoderma gangrenosum: a possible cutaneous complication of levamisole-tainted cocaine abuse. ( 24898775 )
2014
44
Cocaine abuse and confidentiality: a case of retiform purpura in an adolescent patient. ( 24831315 )
2014
45
Application of hygrine and cuscohygrine as possible markers to distinguish coca chewing from cocaine abuse on WDT and forensic cases. ( 24656326 )
2014
46
Facial Cutaneous Necrosis Associated With Suspected Levamisole Toxicity From Tainted Cocaine Abuse. ( 25015925 )
2014
47
Cardiac Fas-dependent and mitochondria-dependent apoptosis after chronic cocaine abuse. ( 24722570 )
2014
48
Acute morphine and cocaine related death after trimethoprim-adultered cocaine abuse. ( 25361939 )
2014
49
Association between smoking, crack cocaine abuse and the discontinuation of combination antiretroviral therapy in Recife, Pernambuco, Brazil. ( 24626414 )
2014
50
Ventral midbrain correlation between genetic variation and expression of the dopamine transporter gene in cocaine-abusing versus non-abusing subjects. ( 22026501 )
2014

Variations for Cocaine Abuse

Expression for Cocaine Abuse

Search GEO for disease gene expression data for Cocaine Abuse.

Pathways for Cocaine Abuse

GO Terms for Cocaine Abuse

Cellular components related to Cocaine Abuse according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.85 DRD2 SIGMAR1 SLC18A2 SLC6A2 SLC6A3 SLC6A4
2 synapse GO:0045202 9.71 HTR3A SIGMAR1 SLC17A8 SNCA
3 membrane raft GO:0045121 9.65 SLC6A2 SLC6A3 SLC6A4
4 neuronal cell body GO:0043025 9.62 HTR3A SLC17A8 SLC6A3 SNCA
5 neuron projection GO:0043005 9.56 SLC17A8 SLC6A2 SLC6A3 SLC6A4
6 axon GO:0030424 9.46 DRD2 HTR3A SLC6A3 SNCA
7 nuclear outer membrane GO:0005640 9.43 SIGMAR1 SNCA
8 cytoplasmic vesicle GO:0031410 9.35 DBH DRD2 SIGMAR1 SLC17A8 SLC18A2
9 axon terminus GO:0043679 8.8 DRD2 SLC17A8 SNCA
10 plasma membrane GO:0005886 10.11 DRD2 GRK3 HTR3A SIGMAR1 SLC18A2 SLC6A2

Biological processes related to Cocaine Abuse according to GeneCards Suite gene sharing:

(show all 30)
id Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 9.89 SLC17A8 SLC18A2 SLC6A2 SLC6A3 SLC6A4
2 response to drug GO:0042493 9.8 DRD2 SLC6A2 SLC6A3 SLC6A4 SNCA
3 response to ethanol GO:0045471 9.77 DRD2 HTR3A SLC6A3
4 chemical synaptic transmission GO:0007268 9.76 DBH SLC18A2 SLC6A2 SNCA
5 response to toxic substance GO:0009636 9.73 DRD2 SLC18A2 SLC6A4
6 positive regulation of multicellular organism growth GO:0040018 9.65 DRD2 SLC6A3
7 associative learning GO:0008306 9.64 DBH DRD2
8 regulation of dopamine secretion GO:0014059 9.64 DRD2 SNCA
9 behavioral response to cocaine GO:0048148 9.63 DRD2 SNCA
10 response to iron ion GO:0010039 9.63 DRD2 SLC6A3
11 regulation of long-term neuronal synaptic plasticity GO:0048169 9.62 DRD2 SNCA
12 response to pain GO:0048265 9.62 DBH SLC6A2
13 locomotory behavior GO:0007626 9.62 DBH DRD2 SLC18A2 SLC6A3
14 synaptic transmission, dopaminergic GO:0001963 9.61 DRD2 SNCA
15 behavioral response to ethanol GO:0048149 9.61 DBH DRD2
16 dopamine metabolic process GO:0042417 9.59 DRD2 SNCA
17 neurotransmitter biosynthetic process GO:0042136 9.58 SLC6A3 SLC6A4
18 ammonium transmembrane transport GO:0072488 9.58 SLC6A3 SLC6A4
19 prepulse inhibition GO:0060134 9.57 DRD2 SLC6A3
20 response to cocaine GO:0042220 9.56 DRD2 HTR3A SLC6A3 SNCA
21 dopamine biosynthetic process GO:0042416 9.55 SLC6A3 SNCA
22 neurotransmitter transport GO:0006836 9.55 SLC17A8 SLC18A2 SLC6A2 SLC6A3 SLC6A4
23 response to amphetamine GO:0001975 9.54 DBH DRD2 SLC18A2
24 adenohypophysis development GO:0021984 9.52 DRD2 SLC6A3
25 dopamine catabolic process GO:0042420 9.51 DBH SLC6A3
26 dopamine transport GO:0015872 9.48 SLC18A2 SLC6A3
27 serotonin transport GO:0006837 9.43 SLC18A2 SLC6A4
28 monoamine transport GO:0015844 9.26 SLC18A2 SLC6A2 SLC6A3 SLC6A4
29 dopamine uptake involved in synaptic transmission GO:0051583 8.92 SLC6A2 SLC6A3 SLC6A4 SNCA
30 transport GO:0006810 10.08 HTR3A SIGMAR1 SLC17A8 SLC18A2 SLC6A2 SLC6A3

Molecular functions related to Cocaine Abuse according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.5 DRD2 SIGMAR1 SLC6A3
2 beta-tubulin binding GO:0048487 9.46 SLC6A2 SNCA
3 symporter activity GO:0015293 9.46 SLC17A8 SLC6A2 SLC6A3 SLC6A4
4 alpha-tubulin binding GO:0043014 9.43 SLC6A2 SNCA
5 neurotransmitter:sodium symporter activity GO:0005328 9.4 SLC6A3 SLC6A4
6 dopamine binding GO:0035240 9.37 DRD2 SLC6A3
7 serotonin transmembrane transporter activity GO:0015222 9.26 SLC18A2 SLC6A4
8 dopamine:sodium symporter activity GO:0005330 9.13 SLC6A2 SLC6A3 SLC6A4
9 monoamine transmembrane transporter activity GO:0008504 8.92 SLC18A2 SLC6A2 SLC6A3 SLC6A4

Sources for Cocaine Abuse

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....